Toby I. Gropen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Toby I. Gropen has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Edoardo Gaude
Pockit Diagnostics Ltd, University of Cambridge, CRUK Cambridge Institute, United Kingdom (E.G.).
2 shared publications - Joshua D. Bernstock
Department of Neurosurgery, Brigham and Women’s Hospital, Mass General Brigham, Boston, Massachusetts
2 shared publications Melissa Gazi
Division of Cerebrovascular Disease, The University of Alabama at Birmingham, Birmingham, AL, United States
2 shared publicationsMichael Minor
Division of Cerebrovascular Disease, The University of Alabama at Birmingham, Birmingham, AL, United States
2 shared publicationsAbimbola Fadairo
University of Alabama at Birmingham Comprehensive Stroke Center, Birmingham, Alabama
1 shared publication- Adam Andrew Dmytriw
Nuffield Department of Surgical Sciences, Medical Sciences Division, University of Oxford, Oxford, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
Prehospital Detection of Large Vessel Occlusion and Intracerebral Hemorrhage Using a Dual-Biomarker Point-of-Care Test
BACKGROUND: Timely identification of stroke subtype is critical for triage and treatment. Existing prehospital stroke scales have limited diagnostic accuracy, especially in differentiating large vessel occlusion (LVO) from intracerebral hemorrhage (ICH). The LVOne point-of-care test measures d -dimer and GFAP (glial fibrillary acidic protein), biomarkers associated with thrombotic and hemorrhagic stroke, enabling biologically informed triage. METHODS: We validated a new version of the LVOne assay using plasma samples from 210 suspected stroke patients presenting within 6 hours of symptom onset, enrolled in the TIME (Testing of Identification Markers for Stroke) prospective observational cohort. This article reports a retrospective (secondary) laboratory analysis of these prospectively collected samples and clinical data. Samples were collected before neuroimaging or thrombolysis. LVOne version 1 combined d -dimer positivity, GFAP negativity, and Field Assessment Stroke Triage for Emergency Destination scoring for LVO detection only; version 2 uses improved GFAP measurement and a clinical decision rule enabling simultaneous diagnosis of LVO and ICH. Diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value) was calculated for each version. Receiver operating characteristic analyses and biomarker correlations with Field Assessment Stroke Triage for Emergency Destination were also performed. RESULTS: Both LVOne versions achieved high accuracy for LVO detection (sensitivity, 0.75; specificity, 0.92; negative predictive value, 0.97). Version 2 improved ICH specificity (0.99 versus 0.90) and positive predictive value (0.83 versus 0.23) versus version 1. Biomarker levels correlated with Field Assessment Stroke Triage for Emergency Destination scores but with limited explanatory power (GFAP R 2 =0.077; d -dimer R 2 =0.047), suggesting added information beyond clinical severity scales. In a specimen-matrix comparison (n=25), qualitative GFAP/ d -dimer classification was concordant across plasma, venous whole blood, and capillary whole blood. CONCLUSIONS: The updated LVOne assay enables simultaneous biomarker-based identification of both LVO and ICH in suspected stroke patients. Its rapid, low-complexity format supports prehospital use and may improve triage, reduce time to treatment, and optimize outcomes. Prospective field validation is warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04292600.
- 1 May 2026
- Published by Wolters Kluwer Health in Stroke: Vascular and Interventional Neurology
- Vol. 6 (3)
Open AccessPrehospital Detection of Large Vessel Occlusion and Intracerebral Hemorrhage Using a Dual-Biomarker Point-of-Care Test
BACKGROUND: Timely identification of stroke subtype is critical for triage and treatment. Existing prehospital stroke scales have limited diagnostic accuracy, especially in differentiating large vessel occlusion (LVO) from intracerebral hemorrhage (ICH). The LVOne point-of-care test measures d -dimer and GFAP (glial fibrillary acidic protein), biomarkers associated with thrombotic and hemorrhagic stroke, enabling biologically informed triage. METHODS: We validated a new version of the LVOne assay using plasma samples from 210 suspected stroke patients presenting within 6 hours of symptom onset, enrolled in the TIME (Testing of Identification Markers for Stroke) prospective observational cohort. This article reports a retrospective (secondary) laboratory analysis of these prospectively collected samples and clinical data. Samples were collected before neuroimaging or thrombolysis. LVOne version 1 combined d -dimer positivity, GFAP negativity, and Field Assessment Stroke Triage for Emergency Destination scoring for LVO detection only; version 2 uses improved GFAP measurement and a clinical decision rule enabling simultaneous diagnosis of LVO and ICH. Diagnostic performance (sensitivity, specificity, positive predictive value, negative predictive value) was calculated for each version. Receiver operating characteristic analyses and biomarker correlations with Field Assessment Stroke Triage for Emergency Destination were also performed. RESULTS: Both LVOne versions achieved high accuracy for LVO detection (sensitivity, 0.75; specificity, 0.92; negative predictive value, 0.97). Version 2 improved ICH specificity (0.99 versus 0.90) and positive predictive value (0.83 versus 0.23) versus version 1. Biomarker levels correlated with Field Assessment Stroke Triage for Emergency Destination scores but with limited explanatory power (GFAP R 2 =0.077; d -dimer R 2 =0.047), suggesting added information beyond clinical severity scales. In a specimen-matrix comparison (n=25), qualitative GFAP/ d -dimer classification was concordant across plasma, venous whole blood, and capillary whole blood. CONCLUSIONS: The updated LVOne assay enables simultaneous biomarker-based identification of both LVO and ICH in suspected stroke patients. Its rapid, low-complexity format supports prehospital use and may improve triage, reduce time to treatment, and optimize outcomes. Prospective field validation is warranted. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04292600.
- Open Access
- 6 December 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Trauma Communications Center Coordinated Severity-Based Stroke Triage: Protocol of a Hybrid Type 1 Effectiveness-Implementation Study
Background:Mechanical thrombectomy (MT) can improve the outcomes of patients with large vessel occlusion (LVO), but a minority of patients with LVO are treated and there are disparities in timely access to MT. In part, this is because in most regions, including Alabama, the emergency medical service (EMS) transports all patients with suspected stroke, regardless of severity, to the nearest stroke center. Consequently, patients with LVO may experience delayed arrival at stroke centers with MT capability and worse outcomes. Alabama's trauma communications center (TCC) coordinates EMS transport of trauma patients by trauma severity and regional hospital capability. Our aims are to develop a severity-based stroke triage (SBST) care model based on Alabama's trauma system, compare the effectiveness of this care pathway to current stroke triage in Alabama for improving broad, equitable, and timely access to MT, and explore stakeholder perceptions of the intervention's feasibility, appropriateness, and acceptability.Methods:This is a hybrid type 1 effectiveness-implementation study with a multi-phase mixed methods sequential design and an embedded observational stepped wedge cluster trial. We will extend TCC guided stroke severity assessment to all EMS regions in Alabama; conduct stakeholder interviews and focus groups to aid in development of region and hospital specific prehospital and inter-facility stroke triage plans for patients with suspected LVO; implement a phased rollout of TCC Coordinated SBST across Alabama's six EMS regions; and conduct stakeholder surveys and interviews to assess context-specific perceptions of the intervention. The primary outcome is the change in proportion of prehospital stroke system patients with suspected LVO who are treated with MT before and after implementation of TCC Coordinated SBST. Secondary outcomes include change in broad public health impact before and after implementation and stakeholder perceptions of the intervention's feasibility, appropriateness, and acceptability using a mixed methods approach. With 1200 to 1300 total observations over 36 months, we have 80% power to detect a 15% improvement in the primary endpoint.Discussion:This project, if successful, can demonstrate how the trauma system infrastructure can serve as the basis for a more integrated and effective system of emergency stroke care.
- 6 December 2021
- Published by Frontiers Media SA in Frontiers in Neurology
- Vol. 12
Open AccessTrauma Communications Center Coordinated Severity-Based Stroke Triage: Protocol of a Hybrid Type 1 Effectiveness-Implementation Study
Background:Mechanical thrombectomy (MT) can improve the outcomes of patients with large vessel occlusion (LVO), but a minority of patients with LVO are treated and there are disparities in timely access to MT. In part, this is because in most regions, including Alabama, the emergency medical service (EMS) transports all patients with suspected stroke, regardless of severity, to the nearest stroke center. Consequently, patients with LVO may experience delayed arrival at stroke centers with MT capability and worse outcomes. Alabama's trauma communications center (TCC) coordinates EMS transport of trauma patients by trauma severity and regional hospital capability. Our aims are to develop a severity-based stroke triage (SBST) care model based on Alabama's trauma system, compare the effectiveness of this care pathway to current stroke triage in Alabama for improving broad, equitable, and timely access to MT, and explore stakeholder perceptions of the intervention's feasibility, appropriateness, and acceptability.Methods:This is a hybrid type 1 effectiveness-implementation study with a multi-phase mixed methods sequential design and an embedded observational stepped wedge cluster trial. We will extend TCC guided stroke severity assessment to all EMS regions in Alabama; conduct stakeholder interviews and focus groups to aid in development of region and hospital specific prehospital and inter-facility stroke triage plans for patients with suspected LVO; implement a phased rollout of TCC Coordinated SBST across Alabama's six EMS regions; and conduct stakeholder surveys and interviews to assess context-specific perceptions of the intervention. The primary outcome is the change in proportion of prehospital stroke system patients with suspected LVO who are treated with MT before and after implementation of TCC Coordinated SBST. Secondary outcomes include change in broad public health impact before and after implementation and stakeholder perceptions of the intervention's feasibility, appropriateness, and acceptability using a mixed methods approach. With 1200 to 1300 total observations over 36 months, we have 80% power to detect a 15% improvement in the primary endpoint.Discussion:This project, if successful, can demonstrate how the trauma system infrastructure can serve as the basis for a more integrated and effective system of emergency stroke care.
- Open Access
- 22 June 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (7) , 1137
A Novel Combination of Blood Biomarkers and Clinical Stroke Scales Facilitates Detection of Large Vessel Occlusion Ischemic Strokes
Acute ischemic stroke caused by large vessel occlusions (LVOs) is a major contributor to stroke deaths and disabilities; however, identification for emergency treatment is challenging. We recruited two separate cohorts of suspected stroke patients and screened a panel of blood-derived protein biomarkers for LVO detection. Diagnostic performance was estimated by using blood biomarkers in combination with NIHSS-derived stroke severity scales. Multivariable analysis demonstrated that D-dimer (OR 16, 95% CI 5–60; p-value < 0.001) and GFAP (OR 0.002, 95% CI 0–0.68; p-value < 0.05) comprised the optimal panel for LVO detection. Combinations of D-dimer and GFAP with a number of stroke severity scales increased the number of true positives, while reducing false positives due to hemorrhage, as compared to stroke scales alone (p-value < 0.001). A combination of the biomarkers with FAST-ED resulted in the highest accuracy at 95% (95% CI: 87–99%), with sensitivity of 91% (95% CI: 72–99%), and specificity of 96% (95% CI: 90–99%). Diagnostic accuracy was confirmed in an independent cohort, in which accuracy was again shown to be 95% (95% CI: 87–99%), with a sensitivity of 82% (95% CI: 57–96%), and specificity of 98% (95% CI: 92–100%). Accordingly, the combination of D-dimer and GFAP with stroke scales may provide a simple and highly accurate tool for identifying LVO patients, with a potential impact on time to treatment.
- 22 June 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (7) , 1137
Open AccessA Novel Combination of Blood Biomarkers and Clinical Stroke Scales Facilitates Detection of Large Vessel Occlusion Ischemic Strokes
Acute ischemic stroke caused by large vessel occlusions (LVOs) is a major contributor to stroke deaths and disabilities; however, identification for emergency treatment is challenging. We recruited two separate cohorts of suspected stroke patients and screened a panel of blood-derived protein biomarkers for LVO detection. Diagnostic performance was estimated by using blood biomarkers in combination with NIHSS-derived stroke severity scales. Multivariable analysis demonstrated that D-dimer (OR 16, 95% CI 5–60; p-value < 0.001) and GFAP (OR 0.002, 95% CI 0–0.68; p-value < 0.05) comprised the optimal panel for LVO detection. Combinations of D-dimer and GFAP with a number of stroke severity scales increased the number of true positives, while reducing false positives due to hemorrhage, as compared to stroke scales alone (p-value < 0.001). A combination of the biomarkers with FAST-ED resulted in the highest accuracy at 95% (95% CI: 87–99%), with sensitivity of 91% (95% CI: 72–99%), and specificity of 96% (95% CI: 90–99%). Diagnostic accuracy was confirmed in an independent cohort, in which accuracy was again shown to be 95% (95% CI: 87–99%), with a sensitivity of 82% (95% CI: 57–96%), and specificity of 98% (95% CI: 92–100%). Accordingly, the combination of D-dimer and GFAP with stroke scales may provide a simple and highly accurate tool for identifying LVO patients, with a potential impact on time to treatment.
- 1 September 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (9) , 2388-2397
Centrally Guided Identification of Patients With Large Vessel Occlusion: Lessons From Trauma Systems
- 1 September 2019
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 28 (9) , 2388-2397
Centrally Guided Identification of Patients With Large Vessel Occlusion: Lessons From Trauma Systems
- 1 March 2018
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 27 (3) , 806-815
Derivation and Validation of the Emergency Medical Stroke Assessment and Comparison of Large Vessel Occlusion Scales
- 1 March 2018
- Published by Elsevier in Journal of Stroke and Cerebrovascular Diseases
- Vol. 27 (3) , 806-815
Derivation and Validation of the Emergency Medical Stroke Assessment and Comparison of Large Vessel Occlusion Scales